What is Plasys300® and what can it be used for?

Plasys300® is a proprietary combination, which is specifically designed to facilitate healthy ageing in men.

Plasys300® is derived from a trusted source of pine bark and rye pollen to ensure the high-quality and purity of the final extract. The final ingredient is manufactured at Pharmactive’s own facilities, which are GMP-certified with other quality and environmental management certifications. 

Taking advantage of the synergic effect of different bio-actives, it offers triple benefits in a single solution:

  • urinary symptom improvement
  • prostate enlargement inhibition
  • hormonal balance

Its low dose avoids the use of multiple ingredients in the same formula, favouring the use of low-size formats, therefore enabling easy swallowing.

Bioative Compounds

Plasys300® is standardized to ≥50% phytosterols (as β–sitosterol) by GC and to ≥1% essential amino
acids by HPLC. β–sitosterol is a phytosterol that has clinical evidence as an inhibitor of testosterone production.1-3

Essential amino acids from rye pollen have a potent antioxidant effect and have been related to anti-inflammatory properties, as well as clinical evidence for palliating benign prostate hyperplasia
symptoms (such as nocturia, urine frequency, bladder emptying and hyperplasia).4-11

Main Mechanisms of Action

Plasys300® acts mainly at three levels in a synergic way:

  1. It inhibits one of the enzymes responsible for testosterone production (5-α-reductase), decreasing its concentration in the prostate and balancing cellular growth factors levels (such as SDGF and EDGF)2 typically altered in an enlarged prostate or BPH.
  2. It blocks the overstimulation of α-adrenergic receptors at the prostate, reducing the urinary tract vasoconstriction as well as the urinary discomfort symptoms.10,12
  3. It has an anti-proliferative effect at the prostatic cells that helps prevent prostate

(1) Bergers A., et al. British J. of Urology. 2000; 85, 842-846; (2) Berges R.R., et al. Lancet. 1995; 345, 1529-1532; (3) Madersbacher S., et al. EAUEBU. 2007; 5, 197-205; (4) Buck A.C., et al. British J. of Urology. 1990; 66, 398-404; (5) Feinblatt H.M. and Gant J.C., J.Maine Med. Assn. 1958; 9, 99- 101; (6) Elist J. Urology. 2006; 67, 60-63; (6) Kimura M., et al. Japan Pharmacol. Ther. 1998; 26, 1801-1806; (7) Talpur N., et al. Mol Cell Biochem. 2003; 250, 21-26; (8) Yasumoto R., et al. Clin Therapy. 1995; 17, 82-86; (9) Inarejos-García A.M., et al. Nutr. Clín. Diet. Hosp. 2017; 37(supl. 1): 45; (10) Caine M., et al. British Journal of Urology. 1976; 48, 255-263; (11) Damrau F., et al. J Am Geriartr Soc. 1962; 10, 426-430; (12) Bartsch G., et al. European Urology. 2000; 37, 367-380;